Media Releases
CLEAR

Media Releases

Selected press releases, quarterly earnings press releases, and Amgen‑issued statements related to biosimilars

2020
Dec. 2020 
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
2019
Dec. 2019 
Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration
FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
Aug. 2019 
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (rituximab)
Jul. 2019 
Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
Jun. 2019 
FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Jan. 2019 
Amgen And Allergan Announce Positive Top-Line Results From Phase 1/Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
2018
Dec. 2018 
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Oct. 2018 
Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe
Mar. 2018 
Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer
Feb. 2018 
Amgen Reports Fourth Quarter and Full Year 2017 Financial Results
Jan. 2018 
European Commission Approves Amgen and Allergan’s MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
2017
Dec. 2017 
Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
Nov. 2017 
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types of Cancer
Oct. 2017 
Amgen Reports Third Quarter 2017 Financial Results
 
Amgen Announces 2017 Fourth Quarter Dividend
Sep. 2017 
Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA™
 
Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
 
FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer
 
Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress
Jul. 2017 
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
 
Amgen Announces 2017 Third Quarter Dividend
 
Amgen Reports Second Quarter 2017 Financial Results
 
Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab)
Jun. 2017 
Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
Apr. 2017 
Amgen Announces Webcast Of 2017 First Quarter Financial Results
Mar. 2017 
European Commission Approves AMGEVITA™ (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
Feb. 2017 
Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
Jan. 2017 
Amgen Receives Positive CHMP Opinion For ABP 501 (Biosimilar Adalimumab) For The Treatment Of Certain Inflammatory Diseases
2016
Dec. 2016 
Amgen and Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab
Nov. 2016 
Amgen and Allergan Submit Biosimilar Biologics License Application For ABP 215 To US Food And Drug Administration
Oct. 2016 
Amgen Announces 2016 Fourth Quarter Dividend
Sep. 2016 
FDA Approves Amgen’s AMJEVITA™ (Adalimumab-Atto) For Treatment of Seven Inflammatory Diseases
Jul. 2016 
Amgen Reports Second Quarter 2016 Financial Results
 
Amgen And Allergan Announce Top-Line Results From Phase 3 Study Evaluating ABP 980 Compared With Trastuzumab In Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
 
Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate To Adalimumab
Jun. 2016 
Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To Adalimumab
Apr. 2016 
Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
Jan. 2016 
FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501
 
Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38
2015
Dec. 2015 
Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501
Nov. 2015 
Amgen's First Biosimilar Biologics License Application for ABP 501 Submitted to US Food And Drug Administration
 
Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab
Oct. 2015 
Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72
Sep. 2015 
Amgen And Allergan Announce Positive Top-line Results From Phase 3 Study of Biosimilar Candidate ABP 215
Jul. 2015 
Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.57
Apr. 2015 
Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48
Feb. 2015 
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis
Jan. 2015 
Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70
2014
Oct. 2014 
Amgen Outlines Strategy, Growth Objectives, And Capital Allocation Plans
 
Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30
 
Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis
 
Amgen Announces Moderate-to-Severe Plaque Psoriasis Data To Be Presented At The 23rd Congress Of The European Academy of Dermatology And Venereology
Feb. 2014 
Amgen Statement on Support for Sound, Science-Based Biosimilar Policies
Jan. 2014 
Amgen's 2013 Revenue Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
2013
Dec. 2013 
Amgen Submits Comments to FDA on Biosimilars Naming Citizens Petition
 
Amgen Supports Distinguishable Naming Policy for Biosimilars
Oct. 2013 
Amgen's Third Quarter 2013 Revenue Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
 
Amgen Statement on Veto for California Biosimilars Bill
Sep. 2013 
Amgen Statement on GPhA Citizen Petition on Naming for Biologics
Apr. 2013 
Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
 
Amgen Welcomes European Commission Report on EU Biosimilars Uptake
Mar. 2013 
Amgen Supports World Health Organization's Proposed Distinguishable Naming Policy for Biosimilars
Jan. 2013 
Amgen Backs States' Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
Previous: clinical trials Next: Amgen in the news